Neisseria gonorrhoeae: This bacteria strain is responsible for about 246,000 infections a year but is not nearly as deadly as the other two threats. Yet neisseria is highly prevalent and is the second most common infection with about 800,000 U.S. cases reported in 2011. About 30% of reported cases of neisseria infection are resistant to currently approved drugs, which is why the U.S. government labels the bacteria an urgent threat.
Cempra (CEMP - Get Report) is developing solithromycin, which in a phase II study demonstrated a 100% cure rate against uncomplicated urogenital gonorrhea. It's not clear how many of these patients had drug-resistant strains. Pre-clinical data suggests solithromycin would have strong activity against resistant strains. Cempra has not disclosed additional development plans in this area as it is looking for non-dilutive funding, which should not be a large hurdle given the need and solithromycin's apparent activity.
Tetraphase has also recently published some data showing eravacycline efficacy in drug-resistant Neisseria gonorrhoeae.
Sobek is long Cempra and Tetraphase.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts